Aktienanalyse zu Elanco Animal Health Inc (ELAN)ELANElanco Animal Health Inc

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.

11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.